AA
CHRS icon

ALPS Advisors’s Coherus Oncology CHRS Stock Holding History

ALPS Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-79,420
Closed -$1.02M – 1042
2022
Q1 		$1.02M Sell
79,420
-9,439
-11% -$120K 0.01% 310
2021
Q4 		$1.42M Sell
88,859
-4,873
-5% -$85.2K 0.02% 324
2021
Q3 		$1.51M Sell
93,732
-6,038
-6% -$88.5K 0.01% 349
2021
Q2 		$1.38M Sell
99,770
-31,925
-24% -$452K 0.01% 370
2021
Q1 		$1.92M Sell
131,695
-11,472
-8% -$195K 0.02% 313
2020
Q4 		$2.49M Buy
143,167
+37,755
+36% +$672K 0.03% 244
2020
Q3 		$1.93M Sell
105,412
-6,429
-6% -$120K 0.03% 240
2020
Q2 		$2M Sell
111,841
-32,448
-22% -$549K 0.03% 237
2020
Q1 		$2.34M Buy
144,289
+2,924
+2% +$54K 0.04% 199
2019
Q4 		$2.54M Buy
+141,365
New +$2.61M 0.02% 208
2015
Q4 		– Sell
-59,228
Closed -$11.9K – 685
2015
Q3 		$11.9K Buy
59,228
+21,717
+58% +$661K 0.01% 206
2015
Q2 		$1.08M Buy
+37,511
New +$948K 0.01% 209

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ALPS Advisors's CHRS Position: Q2 2022 in Review

ALPS Advisors sold out of Coherus Oncology (CHRS) in Q2 2022, closing a stake of 79,420 shares — an estimated $1.02M sold.

ALPS Advisors first reported a position in CHRS in Q2 2015 and held it in 12 quarters. The position peaked at $2.54M in Q4 2019. 176 funds tracked by Wall St. Rank hold CHRS as of Q2 2022.

  • ALPS Advisors reported no remaining Coherus Oncology position as of Q2 2022 after selling out during the quarter.
  • ALPS Advisors sold 79,420 Coherus Oncology shares in Q2 2022, an estimated $1.02M.
  • ALPS Advisors first reported a position in Coherus Oncology in Q2 2015 and held it in 12 quarters.
  • ALPS Advisors's Coherus Oncology position peaked at $2.54M in Q4 2019.
  • 176 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2022.

Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.